Molecular profiling to optimize treatment in non-small cell lung cancer: A review of potential molecular targets for radiation therapy by the translational research program of the Radiation Therapy Oncology Group

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages

  Ausborn, Natalie L ^a   Le, Quynh Thu ^b   Bradley, Jeffrey D ^c   Choy, Hak ^d   Dicker, Adam P ^e   Saha, Debabrata ^d   Simko, Jeff ^f   Story, Michael D ^d   Torossian, Artour ^a   Lu, Bo ^e  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Genomic signatures; Molecular markers; Non small cell lung cancer; Radiation therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTORS; GENOMIC SIGNATURES; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); MOLECULAR CLASSIFICATION; MOLECULAR MARKER; MOLECULAR PROFILING; MOLECULAR TARGETS; NON SMALL CELL LUNG CANCER; PERFORMANCE STATUS; PERSONALIZED MEDICINES; POTENTIAL PARAMETERS; RADIATION THERAPY ONCOLOGY GROUPS; RESEARCH EFFORTS; TRANSLATIONAL RESEARCH; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANTIBIOTICS; BIOLOGICAL ORGANS; CHEMOTHERAPY; DISEASES; GENES; ONCOLOGY; OPTIMIZATION;

RADIOTHERAPY;

2 MORPHOLINO 8 PHENYLCHROMONE; AFATINIB; ANAPLASTIC LYMPHOMA KINASE; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERIBULIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; IPILIMUMAB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NINTEDANIB; NIVOLUMAB; PACLITAXEL; PEMETREXED; PLATELET DERIVED GROWTH FACTOR; POLO LIKE KINASE 1; RETASPIMYCIN; SURVIVIN; TEMSIROLIMUS; VASCULOTROPIN; VELIPARIB;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOMODULATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; SQUAMOUS CELL CARCINOMA; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84862673693     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.056     Document Type: Review

References (98)

1. Pao W, Kris MG, Iafrate AJ, et al. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 2009;15:5317-5322.
2. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
3. Yap TA, Vidal L, Adam J, et al. Phase I trial of irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28:3965-3972.
4. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-11932.
5. Janne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17:1131-1139.
6. Janne P, Reckamp K, Koczywas M, et al. Efficacy and safety of PF-00299804 in patients with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib [Abstract]. J Clin Oncol 2009;27(Suppl.15):8063.
7. Massachusetts General Hospital. Understanding Mechanisms of Acquired Resistance to BIBW2992. [Cited 10 October 2011] Available from: http://clinicaltrials.gov/ct2/show/NCT01074177.
8. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
9. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-2890.
10. Schütze C, Dörfler A, Eicheler W, et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW2992 and BIBW2669 with irradiation in FaDu human squamous cell carcinoma. Strahlentherapie und Onkologie 2007;183:256-264.
11. Bernhard EJ, Stanbridge EJ, Gupta S, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000;60:6597-6600.
12. Johnson ML, Rizvi MS, Ginsberg VA, et al. A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations [Abstract]. J Clin Oncol 2009;29(Suppl.15):8012.
13. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
14. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
15. Socinski MA, Morris DE, Stinchcombe TE, et al. Incorporation of bevacizumab and erlotinib with induction and concurrent carboplatin/paclitaxel and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer [Abstract]. J Clin Oncol 2008;26(Suppl. 20):7517.
16. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-48.
17. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13:3395-3402.
18. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors. J ClinOncol 2005;23:5474-5483.
19. Schiller JH, Larson T, Ou SHI, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3836-3841.
20. Fenton BM, Paoni SF. The Addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res 2007;67:9921-9928.
21. Fenton BM, Paoni SF. Alterations in daily sequencing of Axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response. Radiat Res 2009;171:606-614.
22. Ellis PM, Kaiser R, Zhao Y, et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010;16:2881-2889.
23. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22:1374-1381.
24. Zips D, Le K, Yaromina A, et al. Triple angiokinase inhibition, tumor hypoxia and radiation response of FaDu human squamous cell carcinomas. Radiother Oncol 2009;92:405-410.
25. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059.
26. Yuan R, Kay A, Berg WJ, et al. Targeting tumorgenesis: Development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;27:45.
27. Janmaat ML, Kruyt FA, Rodriguez JA, et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 2003;9:2316-2326.
28. Ekshyyan O, Rong Y, Rong X, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009;8:2255-2265.
29. Konstantinidou G, Bey EA, Rabellino A, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 2009;69:7644-7652.
30. Gupta AK, Cerniglia GJ, Mick R, et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. ASTRO Annual Meeting 2003;56:846e853.
31. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007;448:561-567.
32. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
33. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17:2081-2086.
34. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
35. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-4960.
36. Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010;70:9827-9836.
37. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559-570.
38. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008;26:639-643.
39. Reynolds C, Barrera D, Jotte R, et al. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009;4:1537-1543.
40. Socinski MA. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer. J Clin Oncol 2004;22:4341-4350.
41. Wiedenmann N, Valdecanas D, Hunter N, et al. 130-nm Albumin-bound paclitaxel enhances tumor radiocurability and therapeutic Gain. Clin Cancer Res 2007;13:1868-1874.
42. Keedy VL, Lu B, Horn L, et al. A phase I study of nab-paclitaxel with carboplatin and thoracic radiation in patients with locally advanced NSCLC. [Abstract]. J Clin Oncol 2011;29(Suppl.):7046.
43. Swami U, Chaudhary I, Ghalib M, et al. Eribulin - a review of preclinical and clinical studies. Crit Rev Oncol Hematal 2011. Epub ahead of print.
44. Spira AI, Iannotti NO, Savin MA, et al. Phase II study of eribulin mesylate, a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer. J Clin Oncol 2007;25(Suppl):7546.
45. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-330.
46. Gerster K, Shi W, Waldron J, et al. Targeting Polo-like Kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010;77:253-260.
47. Speirs CK, Hwang M, Kim S, et al. Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res 2011;1:50-68.
48. Wesarg E, Hoffarth S, Wiewrodt R, et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007;121:2387-2394.
49. Qian J, Zou Y, Rahman JS, et al. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 2009;8:101-109.
50. Moretti L, Li B, Lu B. AT-101, a Pan-Bcl-2 Inhibitor leads to radiosensitization of non-small lung cancer. J Thorac Oncol 2010;5:680-687.
51. Shinohara ET, Gonzalez A, Massion PP, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005;103:1685-1692.
52. Lu B, Yi M, Schneider S, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004;64:2840-2845.
53. Iwasa T, Okamoto I, Suzuki M, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008;14:6496-6504.
54. Giaccone G, Zatloukal P, Roubec J, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009;27:4481-4486.
55. Sun Y, Giacalone N, Lu B. Terameprocol, an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in nonsmall cell lung carcinoma. J Thorac Oncol 2011;6:8-14.
56. Sun Y, Giacalone N, Lu B. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol 2011. Epub ahead of print.
57. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-3042.
58. Beckman Research Institute. Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. [Cited 13 September 2011] Available from: http://clinicaltrials.gov/ct/show/NCT01386385.
59. Senra JM, Telfer BA, Cherry KE, et al. Inhibition of PARP-1 by olaparib increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 2011;10:1949-1958.
60. Gangopadhyay NN, Luketich JD, Opest A, et al. Inhibition of poly(ADP-ribose) polymerase induces apoptosis in lung cancer cell lines. Cancer Invest 2011;29:608-616.
61. Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti- CTLA4 antibody in human cancer. CurrOpin Immunol 2006;16:206-213.
62. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8:239-245.
63. Lynch TJ, Bondarenko IN, Luft A, et al. Phase II trial of ipilimumab and paclitaxel/carboplatin in first-line stage IIIb/IV non-small cell lung cancer [Abstract]. J Clin Oncol 2010;28(Suppl 15):7531.
64. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379-5388.
65. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728-734.
66. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent Anti-Programmed Death-1 in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-3175.
67. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;2121-2127.
68. Dacic S, Flanagan M, Cieply K. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Path 2006;125:860-865.
69. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;2046-2051.
70. Bunn PA, Doebele RC. Genetic testing for lung cancer: Reflex vs. clinical selection. J Clin Oncol 2011;1943-1945.
71. Agullo-Ortuno MT, Lopez-Rios F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol 2010;5:1673-1691.
72. Nevins JR, Potti A. Mining gene expression profiles: Expression signatures as cancer phenotypes. Nat Rev Genet 2007;8:601-609.
73. Takada M, Tada M, Tamoto E, et al. Prediction of lymph node metastasis by analysis of gene expression profiles in non-small cell lung cancer. J Surg Res 2004;122:61-69.
74. Guo L, Ma Y, Ward R, et al. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 2006;12:3344-3354.
75. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006;3:e467.
76. Beer DG, Kardia SLR, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824.
77. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 2004;22:811-819.
78. Shedden K, Taylor JMG, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 2008;14:822-827.
79. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008;26:877-883.
80. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-7472.
81. Roepman P, Jassem J, Smit EF, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15:284-290.
82. Subramanian J, Simon R. Gene expression-based prognostic SIgnatures in lung cancer: Ready for clinical use? J Natl Cancer Inst 2010;102:464-474.
83. National Cancer Institute. Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer. [Cited 9 Jan 2011] Available from: http://clinicaltrials.gov/ct2/show/NCT00863512.
84. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
85. Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007;99:1257-1269.
86. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discovery 2011;1:44-53.
87. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-244.
88. Das AK, Bell MH, Nirodi CS, et al. Radiogenomics predicting tumor responses to radiotherapy in lung cancer. Semin Radiat Oncol 2010;20:149-155.
89. Torres-Roca JF, Eschrich S, Zhao H, et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005;65:7169-7176.
90. Amundson SA, Do KT, Vinikoor LC, et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 2008;68:415-424.
91. Eschrich S, Zhang H, Zhao H, et al. Systems biology modeling of the radiation sensitivity network: A biomarker discovery platform. Int J Radiat Oncol Biol Phys 2009;75:497-505.
92. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nature Reviews Genetics 2010;11:685-696.
93. Belvedere O, Berri S, Chalkley R, et al. A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early state lung squamous cell carcinoma. Genomics 2012;1:18-24.
94. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010;465:473-477.
95. Southwest Oncology Group. Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery. [Cited 9 January 2012] Available from: http://clinicaltrials.gov/ct2/show/NCT00334815.
96. UNC Lineberger Comprehensive Cancer Center. Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer. [Cited 9 January 2012] Available from: http://clinicaltrials.gov/ct2/ show/NCT00280150.
97. First People's Hospital of Hangzhou. Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer. [Cited 9 January 2012] Available from: http://clinicaltrials.gov/ct2/show/NCT01494415.
98. National Cancer Institute. Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery. [Cited 9 January 2012] Available from: http://clinicaltrials.gov/ct2/ show/NCT00553462.